| Date | Title | Description |
| 12.08.2026 | Vaderis Therapeutics Secures $152M to Advance HHT Treatment | Vaderis Therapeutics secured $152 million in Series B funding. This landmark investment propels engasertib, a potential first treatment for rare Hereditary Hemorrhagic Telangiectasia (HHT), into global Phase 3 trials. HHT causes severe nose... |
| 11.08.2026 | Vaderis Therapeutics closes USD 152 million Series B Financing |
Together, Vaderis Therapeutics' two milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically d... |
| 11.08.2026 | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing
Tue, Aug 11, 2026 13:00 CET Report this content
EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company'... |
| 11.08.2026 | Vaderis Therapeutics Raises $152M in Series B Funding | Vaderis Therapeutics, a Basel, Switzerland-based provider of targeted therapies for rare vascular diseases, raised $152M in Series B funding.
The round was led by Life Sciences at Goldman Sachs Alternatives and TCGX with participation from ... |
| 14.07.2026 | FORE Biotherapeutics Inks $67.4 Million Series D-2 Extension |
PHILADELPHIA, PA, FORE Biotherapeutics, a company dedicated to developing targeted therapies to treat patients with cancer, announced the closing of an upsized Series D-2 extension financing of $67.4 million.
>> Click here for more f... |
| 11.07.2026 | FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer Drug | FORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor... |
| 10.07.2026 | FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib | FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Funding | Fore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $67.4M in Series D-2 extension funding.
The round was led by SR One, ... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer Therapy | FORE Biotherapeutics Expands Funding for Late-Stage Cancer Program
FORE Biotherapeutics has raised $67.4 million to support the development of its lead targeted cancer therapy, plixorafenib. The round was co-led by SR One, Medicxi, SymBiosi... |
| 03.04.2026 | Lilly покупает британского разработчика лекарства от расстройства сна за $7,8 млрд | Препарат Zepbound компании Eli Lilly & Co. помогает решать одну из самых сложных проблем здравоохранения нашего времени — ожирение. Теперь фармкомпания берется за еще одну серьезную проблему общественного здоровья: расстройства сна.
В с... |
| 19.02.2026 | Altesa BioSciences Raises $75M in Series B Funding | Altesa BioSciences, an Atlanta, GA-based clinical-stage pharmaceutical company raised $75M in Series B funding.
The round was led by Forbion, with participation from Sanofi and existing investors, including Medicxi, Pitango, and Atlantic Pa... |
| 19.02.2026 | Altesa BioSciences: $75 Million Series B Raised For Advancing Vapendavir For Chronic Lung Diseases | Altesa BioSciences, a clinical-stage pharmaceutical company focused on improving outcomes for people with chronic lung diseases, has closed an oversubscribed $75 million Series B financing round to advance development of vapendavir, a first... |
| 15.12.2025 | D3 Bio Secures $108M to Advance Cancer Drug Trials Globally | D3 Bio, a Shanghai-based biotech, just raised $108 million. This Series B funding fuels late-stage trials. The focus? Elisrasib, a drug targeting KRAS G12C-mutant cancers. Trials will span the US, China, and Europe. The company aims for glo... |
| 14.12.2025 | D3 Bio: $108 Million Series B Raised To Fund Global Phase III Trials For Lead KRAS G12C Program | D3 Bio has raised $108 million in a Series B financing round to support late-stage clinical development of its lead oncology candidate and advance a broader pipeline of targeted and immuno-oncology programs.
The Shanghai-based clinical-stag... |
| 12.12.2025 | Temasek-backed D3 Bio secures $108 M Series B funding to advance global clinical programs | A $108 million Series B financing round has been completed, according to D3 Bio, a global clinical-stage biotechnology company dedicated to the discovery and development of novel oncology therapeutics.
A notable group of investors, includin... |
| 10.12.2025 | D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs | SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round.... |
| 10.12.2025 | D3 Bio Secures $108M in Series B Funding | D3 Bio, a Shanghai, China-based clinical-stage biotechnology company, raised $108M in Series B funding.
The round was led by IDG Capital and SongQing Capital. Existing investors WuXi AppTec’s Corporate Venture Fund, Temasek, HSG, MPCi, and ... |
| 21.11.2025 | Capital on Tap secures £500M, the second round of speakers for the Tech.eu Summit 2026, and how EQT uses AI | This week, we tracked more than 70 tech funding deals worth over €2.3 billion and over 10 exits, M&A transactions, rumours, and related news stories across Europe.
In addition to this week's top financials, we've also indexed the most i... |
| 14.11.2025 | Index spinout Medicxi closes Fund V at €500m | - |
| 14.11.2025 | Medicxi Announces €500 Million Fund V | - |
| 14.11.2025 | Medicxi Closes €500 Million Fund To Advance Asset-Centric Biotech Innovation | Medicxi announced the close of its €500 million Medicxi V vehicle, reinforcing the firm’s position as a major European life sciences investor and adding significant capital to expand its long-standing asset-centric company creation strategy... |
| 18.09.2025 | Capital meets care: 10 venture capital firms transforming healthcare across Europe | Venture capital remains one of the cornerstones of Europe’s innovation landscape, fuelling the growth of startups across every sector. In our last list, we spotlighted 15 VC firms focused on sustainability, underlining how investors are sha... |
| 08.09.2025 | Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder | Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company
KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug De... |
| 23.07.2025 | Sanofi to Acquire Vicebio, for US$1.6 Billion | Sanofi (EURONEXT: SAN and NASDAQ: SNY), a Paris, France-based AI-powered biopharma company, acquired Vicebio, a London, UK-based biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, for ... |
| 28.05.2025 | FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 Financing | In the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company's m... |
| 23.05.2025 | FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of Plixorafenib | FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare... |
| 18.03.2025 | Curevo's $110 Million Bet on Shingles Vaccine: A Game Changer in Immunization | In the bustling world of biotechnology, Curevo Vaccine has made headlines with its recent $110 million Series B funding round. This infusion of capital is not just a financial boost; it’s a lifeline for a company on the brink of a significa... |
| 18.03.2025 | Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein Shingles | Curevo Vaccine – a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability – announced the closing of a $110 million Series B round to advance the developm... |
| 17.03.2025 | Curevo Raises $110M in Series B Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding.
The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Ca... |
| 20.12.2024 | Ottimo Pharma: A New Dawn in Cancer Treatment with $140 Million Boost | In the world of biotechnology, every dollar counts. Ottimo Pharma, a New York City-based biotech firm, has just raised over $140 million in a Series A funding round. This infusion of capital is not just a financial milestone; it’s a beacon ... |
| 20.12.2024 | Ottimo Pharma: Over $140 Million (Series A) Raised To Advance Bifunctional Medicines | Ottimo Pharma – a private biotech company pioneering bifunctional medicines to extend the lives of people with cancer – announced the completion of a Series A financing round of over $140 million. The funding round was led by OrbiMed, Avoro... |
| 11.10.2024 | Europe takes the lead: New ranking reveals surprising shift in the global venture capital landscape | The venture capital landscape, a critical driver of innovation and startup growth, has long been dominated by U.S.-based firms. These firms traditionally lead the way in funding emerging technologies and disruptive businesses globally. Howe... |
| 08.04.2024 | Medicxi Announces $40m investment in D3 Bio | - |
| 08.04.2024 | D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline | SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, ... |
| 23.02.2024 | Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline | - |
| 11.02.2024 | Medicxi merges 6 dermatology biotechs into one, adds $100M funding for launch | What do you get when you merge six dermatology disease-focused biotechs into one? Medicxi plans to find out.
The London-headquartered venture capital firm is combining six of its portfolio companies together, adding in a $100 million shot o... |
| 02.10.2023 | 'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023 | While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had problems bringing in money.
In fact, both Forbion and BioGeneration Ventures announced their largest ... |
| 28.07.2023 | Medicxi IV to boost the European Life sciences sector with $400m | |
| 27.07.2023 | Medicxi Announces $400m Medicxi IV | - |
| 27.07.2023 | Medicxi Launches $400M Fund IV | Medicxi, a London, UK- Geneva, Switzerland- and Jersey-based life sciences investment firm, announced its $400m Fund IV.
Medicxi IV will continue to support drug hunters with clear product visions to deliver transformative therapies for pat... |
| 19.01.2023 | The Week in Agrifoodtech: Sollum Technologies nabs $30m; phantom carbon credits & food delivery shutdowns | Sollum Technologies raised the largest funding round this week, for its programmable LED lighting for greenhouses. Multus Biotechnology also secured funding, while The Guardian and others unveiled an investigation into a nonprofit for what ... |
| 17.02.2021 | Three Cambridge spin-outs join Centessa Pharmaceuticals, launched with a $250m Series A round | Three Cambridge spin-outs join Centessa Pharmaceuticals, launched with a $250m Series A round
17-02-2021
ApcinteX, Morphogen-IX, Z Factor join seven other privately held biotech companies in a new type of pharmaceutical R&D model.
Cente... |
| 19.11.2020 | SynOx Therapeutics raises €37M in Series A Financing | DUBLIN, Nov. 19, 2020 /PRNewswire/ — SynOx Therapeutics Ltd (“SynOx”), a clinical stage bio pharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forb... |
| 22.09.2020 | Medicxi announces the closing of its first €200 million Secondary Fund, led by Pantheon with co-lead LGT Capital Partners | - |
| 23.09.2019 | Divide & Conquer Launches With $13M in Series A Financing | Divide & Conquer, a Cambridge, UK-based biotechnology company, emerged from stealth with £10m (approximately $13.1m) in Series A financing.
Medicxi made the investment.
Divide & Conquer initially focuses on glioblastoma, a lethal fo... |
| 19.07.2019 | Medicxi closes a €400M Fund to back biopharma entrepreneurs | |
| 19.07.2019 | Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters | - |
| 02.04.2019 | Aura Biosciences cierra una ronda Serie D de $40M liderada por Medicxi, acuden Ysios, Advent Life, Aris Bioscience, Chiesi, ColumbusVP y Lundbeckfonden | 02/04/2019
Nota de prensa
AURA BIOSCIENCES CIERRA UNA RONDA SERIE D DE $40 MILLONES LIDERADA POR MEDICXI, ACUDEN YSIOS CAPITAL, ADVENT LIFE SCIENCES, ARIS BIOSCIENCE, CHIESI, COLUMBUSVP Y LUNDBECKFONDEN.
Aura Biosciences, a leader in the... |
| 09.07.2018 | Morphogen-IX announces appointment of CEO and SAB members | Morphogen-IX announces appointment of CEO and SAB members
09-07-2018
Morphogen-IX Ltd, a preclinical biotechnology company focused on the development of bone morphogenetic proteins for the treatment of pulmonary arterial hypertension (PAH),... |
| 09.07.2018 | Morphogen-IX announces appointment of CEO and SAB members | Morphogen-IX Ltd, a preclinical biotechnology company focused on the development of bone morphogenetic proteins for the treatment of pulmonary arterial hypertension (PAH), has announced the appointment of Professor Nick Morrell as CEO. Morr... |
| 07.06.2018 | TPG Leads $85M Series C for SutroVax | SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of an upsized $85 million Serie... |
| 20.03.2018 | Medicxi founds biotech creation engine C21Med | Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson ... |
| 20.03.2018 | Medicxi founds biotech creation engine C21Med | Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson ... |
| 20.01.2018 | Startup fundraising and exits look bullish for bio and health | Joanna Glasner Contributor
Joanna Glasner is a reporter for Crunchbase.
More posts by this contributor
What does it take to be a startup that raises huge sums quickly?
Not a minimalist? Startups will gladly store, manage and deliver your it... |
| 08.01.2018 | This 1-Year-Old Pharma Startup Landed a $1B Buyout | John Hood formed Impact Biomedicines to carry on an abandoned clinical research. John Moore/Getty Images
Impact Biomedicines, a San Diego, Calif.-based startup that recently closed its first round of fundraising, is now an overnight unicorn... |
| 15.06.2017 | Medicxi Launches $300M Late-Stage Life Sciences Fund | Medicxi, a London and Geneva-based life sciences venture capital firm, closed its first late-stage fund, at $300m.
Cornerstone strategic investors in MG1 are Novartis, Verily, an Alphabet company, and the European Investment Fund (EIF).
The... |
| 15.06.2017 | Google backs Swiss based life sciences fund | |
| 04.05.2017 | Z Factor announces £7 million Series A funding to bring lung treatment to clinic | Z Factor announces £7 million Series A funding to bring lung treatment to clinic
04-05-2017
Z Factor Limited announced that it has completed a £7 million Series A investment led by existing investor Medicxi. Cambridge Enterprise & Cambr... |
| 04.05.2017 | Z Factor announces £7 million Series A funding to bring lung treatment to clinic | Z Factor Limited announced that it has completed a £7 million Series A investment led by existing investor Medicxi. Cambridge Enterprise & Cambridge Innovation Capital have also joined in the founding round.
Add This Share Buttons
Found... |
| 16.02.2017 | SuperX Completes $11M Series A Funding | SuperX Ltd, a Cambridge, UK-based biopharmaceutical company, completed an $11m Series A funding.
The round was led by Medicxi with participation from Johnson & Johnson Innovation – JJDC, Inc., the corporate venture arm of Johnson & ... |
| 04.09.2016 | The biotech empires of Silicon Valley and Europe | Bérénice Magistretti Contributor
Bérénice Magistretti is a Swiss freelance writer based in San Francisco. She focuses on startups in Saudi Arabia, Switzerland and emerging markets.
More posts by this contributor
Disrupting the world of scie... |
| - | SynOx Therapeutics raises €37M in Series A Financing | Dublin, Ireland, November 19, 2020 –SynOx Therapeutics Ltd (“SynOx”), a clinical stage biopharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbio... |
| - | GSK fires ex-Operation Warp Speed chief Moncef Slaoui over ‘substantiated’ sexual harassment claims | Moncef Slaoui was fired as Galvani Bioelectronics board chairman over “substantiated” allegations of sexual harassment, pharmaceuticals giant GlaxoSmithKline said.
Slaoui was chief scientist of the U.S. government’s Covid vaccine developmen... |
